mouse anti-il-1r1  (Santa Cruz Biotechnology)

Journal: Science advances

Article Title: Earlier onset of chemotherapy-induced neuropathic pain in females by ICAM-1-mediated accumulation of perivascular macrophages.

doi: 10.1126/sciadv.adu2159

Figure Lengend Snippet: Fig. 6. ICAM-1 and IL-1α released by endothelial cells synergistically promote macrophage infiltration in female mice following BTZ. (A) Il1a, Ccl5, and Ccl1 mRNA levels in the dorsal horn of female mice. n = 5 to 8. (B) Immunofluorescence image of IL-1α (green) in vascular endothelial cells (red). Scale bars, 50 μm (low) or 20 μm (high). (C) Double immunofluorescence staining of CCL1 (green) and vascular endothelial cells (red). Scale bars, 50 μm (low) or 20 μm (high). (D and E) Coimmunostaining image of F4/80 (green) and CD31 (red) in the spinal dorsal horn and the statistical graph. Scale bar, 200 μm. n = 5. (F) Intrathecal injection of IL-1α siRNA attenuated the mechanical allodynia induced by BTZ. n = 5. (G) Immunofluorescence image shows IL-1R1 (red) expression in macrophages (green). Scale bar, 10 μm. (H and I) Intrathecal IL-1R1 injection inhibited the up-regulation of F4/80 (green) and CD31 (red) in the near vascular of the spinal dorsal horn. Scale bar, 200 μm (H). The number of F4/80high cells in the dorsal horn of the spinal cord [(I), left]. The percentage of F4/80high area among CD31+ area [(I), right]. n = 4 to 5. (J and K) Immunostaining shows F4/80 (green) and CD31 (red) expression in the spinal dorsal horn. Scale bar, 200 μm (J). The number of F4/80high cells in the dorsal horn of the spinal cord [(K), left]. The percentage of F4/80high area among CD31+ area [(K), right]. n = 5. (L) Intrathecal injection of IL-1α siRNA attenuated the mechanical allodynia induced by BTZ. n = 5. Significance: *P < 0.05, #P < 0.05, **P < 0.01, and ##P < 0.01.

Article Snippet: For neutralizing antibodies CCL1 (20 μg/kg; R&D Systems, MAB845) and IL- 1R1 (20 μg/kg; Bio X Cell, BE0256), mice were administered intrathecally 30 min before the injection of BTZ or the IL1R1 ligand, IL- 1α.

Techniques: Immunofluorescence, Double Immunofluorescence Staining, Injection, Expressing, Immunostaining

Journal: bioRxiv

Article Title: IL-1R1 Blockade Enhances CD40 Agonist-Mediated Immune Responses but Fails to Increase Efficacy or Mitigate Hepatotoxicity in Pancreatic Cancer

doi: 10.1101/2025.02.23.639774

Figure Lengend Snippet: Mice bearing 9-day-old orthotopic PDAC tumors (confirmed by luminescence imaging) were treated every 3 days with the indicated antibodies (200 µg/mouse, intraperitoneal). (a) Bulk transcriptomic analysis of orthotopic PDAC tumors after 2 weeks of treatment initiation (*p < 0.05; unpaired t-test, n = 2 mice/group). (b) Kaplan-Meier survival curves (log-rank test, n = 5-6 mice/group). (c) Tumor growth kinetics in subcutaneous PDAC-bearing mice treated every 3 days with agonistic CD40 antibody, anti-IL-1R1 antibody, their combination, or left untreated (****p < 0.0001; two-way ANOVA, n = 5-8 mice/group). (d) Representative H&E-stained tumor sections showing necrosis after 2 weeks of treatment (n = 3-4 mice/group). (e) Quantification of necrotic areas (**p < 0.01; one-way ANOVA, n = 3-4 mice/group). (f) Flow cytometric analysis of PMN-MDSCs in peripheral blood after 2 weeks of treatment (*p < 0.05; unpaired Student’s t-test, n = 5 mice/group). (g) Volcano plot of differentially expressed genes (DEGs) in subcutaneous PDAC tumors treated with anti-IL-1R1 versus untreated controls (red: upregulated; green: downregulated; 546 up, 530 down; p ≤ 0.05, log2FC ≥ 0). (h–i) Gene Ontology (GO) enrichment analysis of DEGs from (g), showing significantly upregulated (h) and downregulated (i) biological processes. (j) Volcano plot of DEGs comparing combination therapy (CD40 + anti-IL-1R1) versus CD40 monotherapy (524 up, 534 down; p ≤ 0.05, log2FC ≥ 0). (k–l) GO enrichment analysis of DEGs from (j), highlighting upregulated (k) and downregulated (l) pathways. (m) Gene Set Enrichment Analysis (GSEA) plots demonstrating the enrichment of indicated gene sets in the combination therapy group compared to CD40 monotherapy.

Article Snippet: Beginning 9 days after tumor implantation, subcutaneous and orthotopic PDAC-bearing mice were treated with anti-IL-1R1 (Clone JAMA-147, BioXCell) or isotype control antibodies (BioXCell) administered intraperitoneally.

Techniques: Imaging, Staining

Journal: bioRxiv

Article Title: IL-1R1 Blockade Enhances CD40 Agonist-Mediated Immune Responses but Fails to Increase Efficacy or Mitigate Hepatotoxicity in Pancreatic Cancer

doi: 10.1101/2025.02.23.639774

Figure Lengend Snippet: Mice bearing 9-day-old subcutaneous PDAC tumors were treated as indicated. (a-b) Serum ALT (a) and AST (b) levels were measured 48 hours after treatment initiation using the COBAS INTEGRA 400 Plus analyzer. *p < 0.01, Wilcoxon non-parametric test; n = 6-9 mice/group. Data represent results combined from two independent experiments. (c) Representative H&E-stained liver histology images from mice collected one week after treatment initiation (n = 3 mice/group, two treatments administered). (d) Cumulative quantification of immune infiltration and histological changes (n = 3 mice/group). (e-f) Serum ALT and AST levels measured after 9 days (e) and 3 weeks (f) of treatment initiation. Combo: agonistic CD40 + anti-IL-1R1 antibody. (g-h) Transcriptomic profiling of the liver from PDAC-bearing mice one week after treatment initiation (two treatments total). KEGG pathway enrichment analysis comparing agonistic CD40 vs. no treatment (g) and combo vs. agonistic CD40 (h). The dot plot highlights pathways associated with liver function, toxicity, and immune infiltration. Dot size represents the number of genes involved (Count), while color intensity reflects statistical significance (−log10 p-value). Upregulated pathways are marked with upward triangles (▴), and downregulated pathways with downward triangles (▾). Pathways with p-value < 0.05 are considered significantly enriched.

Article Snippet: Beginning 9 days after tumor implantation, subcutaneous and orthotopic PDAC-bearing mice were treated with anti-IL-1R1 (Clone JAMA-147, BioXCell) or isotype control antibodies (BioXCell) administered intraperitoneally.

Techniques: Staining

Journal: bioRxiv

Article Title: IL-1R1 Blockade Enhances CD40 Agonist-Mediated Immune Responses but Fails to Increase Efficacy or Mitigate Hepatotoxicity in Pancreatic Cancer

doi: 10.1101/2025.02.23.639774

Figure Lengend Snippet: Mice bearing 9-day-old subcutaneous PDAC tumors were treated as indicated. Graphs show tumor growth at indicated time points. Figure: Tumor growth kinetics in mice bearing 9-day-old subcutaneous PDAC tumors treated as indicated. Tumor area (mm 2 ) was measured over 27 days following treatment initiation. Treatment groups included: no treatment (NO Tx), anti-Ly6G, agonistic CD40 (AgoCD40), AgoCD40 combined with anti-Ly6G, and AgoCD40 combined with anti-IL-1R1. Data represent mean ± SEM (n = 6-9 mice per group). Statistical significance was determined by two-way ANOVA with Tukey’s post hoc test. ***p < 0.001, ****p < 0.0001.

Article Snippet: Beginning 9 days after tumor implantation, subcutaneous and orthotopic PDAC-bearing mice were treated with anti-IL-1R1 (Clone JAMA-147, BioXCell) or isotype control antibodies (BioXCell) administered intraperitoneally.

Techniques:

Journal: EBioMedicine

Article Title: IL-1 receptor 1 signaling shapes the development of viral antigen-specific CD4 + T cell responses following COVID-19 mRNA vaccination.

doi: 10.1016/j.ebiom.2024.105114

Figure Lengend Snippet: Fig. 2: SARS-CoV-2 Spike (S) protein-specific memory CD4+ T cells in healthy subjects immunized with COVID-19 mRNA vaccine have a distinct expression pattern of molecules as determined by CyTOF. (a) Flow cytometric analysis of IL-1R1 and IL-1R2 expression by indicated cell subsets showing expression levels of IL-1R1 and IL-1R2 (mean fluorescence intensity or MFI) in 5 healthy subjects immunized with COVID-19 mRNA vaccine. Left pannels, representative histograms. (b–d) CyTOF analysis showing distinct metaclusters in CD4+ T cells specific for S protein, Flu and CMV. PBMCs of COVID-19 mRNA vaccinated healthy individuals were incubated overnight with or without S protein overlapping peptides, Flu or CMV lysates followed by CyTOF analysis. CD4+ T cell populations indicated above the t-SNE plots in Fig. 1b were identified in 35 samples from 5 subjects according to the gating strategy as in Fig. 1a and further analyzed using using PhenoGraph and metaclustering. (b) t-SNE plots showing distinct metaclusters in indicated CD4+ T cells. Numbers 1 and 2 in the t-SNE plot of all cells indicate metaclusers 1 and 2, respectively. Unstim, unstimulated. (c) Heatmap showing expression levels of indicated molecules by individual metaclusters. (d) Frequency of metaclusters 1 and 2 in S protein-, Flu- and CMV-specific OX40+4-1BB+ CD4+ T cells. Bars and error bars indicate mean and 95% CI. P-values by one-way ANOVA with Dunnett’s post hoc analysis.

Article Snippet: For neutralizing IL1R1, the immunized mice were administered intraperitoneally with 100 μl of anti-IL-1R1 neutralizing antibody (20 μg per mouse, R&D Systems, Minneapolis, MN) at 1 day before, on the day, and 1 day after the 1st and 2nd doses of immunization, respectively.

Techniques: Expressing, Incubation

Journal: EBioMedicine

Article Title: IL-1 receptor 1 signaling shapes the development of viral antigen-specific CD4 + T cell responses following COVID-19 mRNA vaccination.

doi: 10.1016/j.ebiom.2024.105114

Figure Lengend Snippet: Fig. 4: IL-1R1 expessing memory CD4+ T cells specific for SARS-CoV-2 spike (S) protein increase in healthy subjects following the 2nd dose of COVID-19 mRNA vaccine, correlating with anti-S protein IgG production. (a–f) PBMCs of healthy subjects (n = 7) were obtained before and 3–4 weeks after the 1st and 2nd doses of Pfizer-BioNTech or Moderna COVID-19 mRNA vaccine. Cells were incubated overnight with or without S protein overlapping peptides and analyzed by CyTOF. CD4+ T cell populations indicated above the t-SNE plots in (b) were identified according to the gating strategy as in Fig. 1a and further analyzed using using PhenoGraph and metaclustering. (a) Blood collection time points (T). (b) t-SNE plots showing distinct metaclusters in indicated CD4+ T cell populations at T1 and T2. Numbers 1 and 2 in the t-SNE plot of all cells indicate metaclusers 2 and 4, respectively. (c) Heatmap showing expression levels of indicated molecules by individual metaclusters. (d) Graph showing the frequency of metaclusters 2 and 4 at T1 and T2. Bars and error bars indicate mean and 95% CI. P-values were obtained by the paired t-test. (e–f) The relationship of geometric mean metal intensities (GMMI) of IL-1R1 (e) and IL-1R2 (f) expressed on spike protein- specific OX40+4-1BB+ CD4+ T cells with serum anti-s protein IgG levels. 95% CI for correlation coefficient are 0.0015–0.96 (e, 1st dose), 0.039–0.96 (e, 2nd dose), −0.98 to −0.39 (f, 1st dose), −0.52 to 0.88 (f, 2nd dose). Sera were obtained at 10–14 days after the 1st and 2nd doses of COVID-19 mRNA vaccine. P and r values were obtained by Pearson correlation.

Article Snippet: For neutralizing IL1R1, the immunized mice were administered intraperitoneally with 100 μl of anti-IL-1R1 neutralizing antibody (20 μg per mouse, R&D Systems, Minneapolis, MN) at 1 day before, on the day, and 1 day after the 1st and 2nd doses of immunization, respectively.

Techniques: Incubation, Expressing

Journal: EBioMedicine

Article Title: IL-1 receptor 1 signaling shapes the development of viral antigen-specific CD4 + T cell responses following COVID-19 mRNA vaccination.

doi: 10.1016/j.ebiom.2024.105114

Figure Lengend Snippet: Fig. 5: Administrating anti-IL-1R1 neutralizing antibody decreases spike protein (S) -specific CD4+ T cells expressing IFN-γ in mice immunized with COVID-19 mRNA vaccine. (a) Schematic diagrm showing IL-1R1 neutralizing antibody administration schedule in C57BL/6 mice immunized with BNT162b2 COVID-19 mRNA vaccine. (b–c) Flow cytometric analysis of IFN-γ+, TNF-α+, and IL-2+ CD4+ T cells in splenocytes from unvaccinated, vaccinated, and vaccinated mice treated with anti-IL-1R1 neutralizing antibody (Ab) (n = 13). For intracelluar cytokine analysis, splenocytes were incubated overnight with or without S protein overlapping peptides. (d) Anti-S protein IgG levels were determined in sera from the same mice (n = 13). Bars and error bars indicate mean and 95% CI. P-values were obtained by the unpaired t-test.

Article Snippet: For neutralizing IL1R1, the immunized mice were administered intraperitoneally with 100 μl of anti-IL-1R1 neutralizing antibody (20 μg per mouse, R&D Systems, Minneapolis, MN) at 1 day before, on the day, and 1 day after the 1st and 2nd doses of immunization, respectively.

Techniques: Expressing, Incubation

Journal: EBioMedicine

Article Title: IL-1 receptor 1 signaling shapes the development of viral antigen-specific CD4 + T cell responses following COVID-19 mRNA vaccination.

doi: 10.1016/j.ebiom.2024.105114

Figure Lengend Snippet: Fig. 6: SARS-CoV-2 spike (S) protein-specific memroy CD4+ T cells in patients with primary antibody deficiency (PAD) express IL-1 receptor 1 after COVID-19 vaccination, without showing correlation with serum anti-S protein IgG levels. PBMCs were obtained from patients with PADs (4 CVID and 8 other PADs) following the 1st and 2nd doses of COVID-19 mRNA vaccine. Cells were incubated overnight with or without S protein overlapping peptides followed by flow cytometric analysis. (a) Flow cytometric analysis of IL-1R1 expression by indicated CD4+ T cell subsets. Representative histograms and scatter graphs showing mean fluorescence intensity (MFI) of IL-1R1. (b) Heatmap illustrating the expression levels of indicated molecules (z-scores of MFI) on CD4+ T cell subsets defined by the expression of OX40 and 4-1BB. Bars and error bars indicate mean and 95% CI (a). P-values were obtained by ANOVA (a).

Article Snippet: For neutralizing IL1R1, the immunized mice were administered intraperitoneally with 100 μl of anti-IL-1R1 neutralizing antibody (20 μg per mouse, R&D Systems, Minneapolis, MN) at 1 day before, on the day, and 1 day after the 1st and 2nd doses of immunization, respectively.

Techniques: Incubation, Expressing